US FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis

The US Food and Drug Administration (FDA) has accepted Cogent Biosciences, Inc.’s New Drug Application (NDA) for bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2027.